
|Articles|November 6, 2012
NovaBay receives $2.6M to advance Aganocide research
NovaBay Pharmaceuticals has received $2.6 million from partner Galderma for the clinical advancement of NovaBay’s “non-antibiotic, anti-infective” Aganocide compound NVC-422, a topical formulation for impetigo treatment.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Clinicians See Intersection of Weight Loss and Facial Aging
2
The “6-7” Advances for Dermatologists to Look Forward to in 2026
3
Soquelitinib Phase 1 Data Show Sustained Clinical Improvement With Extended Treatment in AD
4
Q&A: Saami Khalifian, MD, FAAD, on Integrating BOTOX Cosmetic into Lower Face and Neck Rejuvenation
5


















